TORONTO, Oct. 16, 2014 /CNW/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that it will present at the Immunogenicity for Biotherapeutics Conference on Tuesday, October 21, 2014 in Boston, Massachusetts.
Dr. Jaymie R. Sawyer, SQI Diagnostics' Vice President of Research and Development, will be presenting data produced during the development of several multiplexed assays for its pharma and biotech customers over the last twelve months. These custom assays were developed to characterize the pre-clinical and clinical immunogenicity of novel protein therapeutics. Immunogenicity is an aspect of drug safety important for biologic drugs.
"We are pleased to be a part of this very prestigious conference," said Andrew Morris, CEO of SQI Diagnostics. "This event brings together the world's leading experts and representatives from all sectors of pharma and biotechnology drug development and gives us the opportunity to share our novel multiplexing applications in drug development testing. Over the past year, we have made significant progress in our work with our pharma and biotech customers and believe our unique products will prove to be beneficial to our customers who are large, global pharmaceutical companies.
The presentation will be available after October 22 on the corporate website at http://sqidiagnostics.com/resources.
Please visit our website for our most recent shareholder update at http://sqidiagnostics.com/about/investors.
For more information, please contact:
Investor Relations Contact:
Chief Executive Officer
416.674.9500 ext. 229
Sales and Marketing Contact:
Vice President, Global Commercial Operations
This press release contains certain forward-looking statements, including, without limitation, statements containing the words "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "believe", "in the process", "benefits", "leading to", "possible" "is subject to" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to: our ability to market and sell our novel multiplexing technologies and detection platforms; our ability to maintain any technical or product advantages; our ability to continue to market and sell our products; SQI's ability to increase customer orders and manufacturing volumes; adverse changes in general economic conditions; impact of healthcare reform legislation; and, SQI's ability to raise additional funds in the future on acceptable terms or at all. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company's ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE: SQI Diagnostics Inc.
For further information: Investor Relations Contact: Andrew Morris, Chief Executive Officer, 416.674.9500 ext. 229, [email protected]; Sales and Marketing Contact: Russ Peloquin, Vice President, Global Commercial Operations, 913.484.9022, [email protected]